chrisvoncsefalvay/vaers-outcomes huggingface dataset:
J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 BACTEREMIA J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 BACTEREMIA R09.02 HYPOXIA 4/15/2023 BACTEREMIA J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 WEAKNESS J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 WEAKNESS R09.02 HYPOXIA 4/15/2023 WEAKNESS J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 PNEUMONIA J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 PNEUMONIA R09.02 HYPOXIA 4/15/2023 PNEUMONIA J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 HYPERKALEMIA J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 HYPERKALEMIA R09.02 HYPOXIA 4/15/2023 HYPERKALEMIA J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 CHOLEDOCHOLITHIASIS W ACUTE PANCREATITIS J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 CHOLEDOCHOLITHIASIS W ACUTE PANCREATITIS R09.02 HYPOXIA 4/15/2023 CHOLEDOCHOLITHIASIS W ACUTE PANCREATITIS J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 PNEUMONIA J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 PNEUMONIA R09.02 HYPOXIA 4/15/2023 PNEUMONIA J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 ACUTE RENAL FAILURE, UNSPECIFIED J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 ACUTE RENAL FAILURE, UNSPECIFIED R09.02 HYPOXIA 4/15/2023 ACUTE RENAL FAILURE, UNSPECIFIED J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 DIASTOLIC HEART FAILURE, ACUTE J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 DIASTOLIC HEART FAILURE, ACUTE R09.02 HYPOXIA 4/15/2023 DIASTOLIC HEART FAILURE, ACUTE J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 DIASTOLIC HEART FAILURE, ACUTE J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 4/20/2023 DIASTOLIC HEART FAILURE, ACUTE R09.02 HYPOXIA 4/15/2023 DIASTOLIC HEART FAILURE, ACUTE
a few min p/vax pt c/o dizziness & was leaning on the back of mom who was w/pt;pt face became pale & slowly slumped down to the floor w/o guidance;pt given Epi & 911 called;pt did not totally pass out;BP 110/80,P82,R15 pt taken to hosp;
c/o hot & swollen arm;couldn't lift up arm;placed on ATB doesn't know name of ATB;
says arm hurt bad enough that it impacted sleep; it impacted sleep; Reports doesn't feel well; is very tired; This case was reported by a consumer via sales rep and described the occurrence of pain in arm in a 56-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st April 2020, the patient received the 1st dose of Shingrix .5 ml. In April 2020, less than a day after receiving Shingrix, the patient experienced pain in arm, sleep disturbance, feeling unwell and tiredness. On an unknown date, the outcome of the pain in arm, feeling unwell and tiredness were not recovered/not resolved and the outcome of the sleep disturbance was unknown.   The reporter considered the pain in arm, sleep disturbance, feeling unwell and tiredness to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The patient's age could be 55 or 56 years old. Reporter said arm hurt bad enough that it impacted sleep.  Reporter does not feel well, was very tired.  Reporter believed the events to be related to vaccination.
Patient developed a severe headache in her forehead on the evening of Saturday, Nov. 14th.  A few hours after patient was vaccinated on Nov. 12th, she said she did not feel "the best".  The next afternoon (Friday, Nov. 13th) she felt achey and tired.  After some rest she felt a little better.  However, on Saturday, Nov. 14th, she progressively felt worse until that night when she went to bed with a headache.  Other than a couple of days following hospitalization and IV meds, patient has suffered a headache every second of every day since November 14th.  She has missed approximately 2/3 of the school days since the headache started.
Information has been received from a Nurse at the physician's office who heard from another Nurse that a patient came in to the office to receive the third dose of GARDASIL and the friend of the patient told her not to get the third dose because she knew of another girl that received the third dose of GARDASIL and died "within the last month" (cause of death not reported). It was unknown if the patient sought medical attention. Attempts are being made to verify the existence of an identifiable patient. Additional information has been requested.
Ongoing heart palpitations, breathlessness, tremulous hands, jittery feeling, sweating, PMS symptoms earlier and worse than usual. EKG showed PVCs.
Patient developed body wide tremor, lightheaded, dizzy, diaphoretic, nausea, vomiting, numbness and tingling bilateral hands and feet.
CHILLS; SORE ARM; FEVER; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031) dose was not reported, administered on 15-MAR-2021 on Left Deltoid for prophylactic vaccination. No concomitant medications were reported. On 15-MAR-2021, the subject experienced chills. On 15-MAR-2021, the subject experienced sore arm. On 15-MAR-2021, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, and sore arm on 17-MAR-2021, and had not recovered from fever. This report was non-serious.
patient reported loss of taste, loss of appetite, pain, swelling, fatigue, nausea and severe diarrhea
Information has been received on 12-MAR-2019 from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 17-DEC-2014, the patient was administered the ZOSTAVAX vaccine (lot # and route not specified) by a physician. On an unspecified date, the patient was treated by a physician for shingles as a result of vaccination with ZOSTAVAX. The outcome was not provided. Additional information has been requested.
Pt c/o dizziness, nausea and feeling flushed.  Vital signs BP 160-90; HR 79; Resp 16 O2 Sat 99% Skin warm and dry ; good cap refil; breath sounds clear bilaterally; no wheezing.  Pt rested in supine position.  Given Water and provided reassurance.    Rested for 15 min.  Moved to upright position, denies nauses or dizziness.  BP146/90, HR 78, Reso 16, O2 sat 99%.  Patient discharged home with husband.
Vaccines given 7/9/12 at noon. 7/10/12 9 am mild (R) ankle pain. 9 pm swelling & moderately sever pain (R) ankle - no redness or warmth almost fully relieved with 600 mg ibuprofen - ice/topicals by next am/ Reactive Arthritis?
gave a 16 year old an adult dose of Havrix; gave a 16 year old patient an adult dose of Havrix; This case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 16-year-old male patient who received HAV (Havrix 1440 adult) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Havrix 1440 adult and Havrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Havrix 1440 adult and Havrix Pre-Filled Syringe Device, the patient experienced accidental overdose and adult product administered to child. On an unknown date, the outcome of the accidental overdose and adult product administered to child were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional deails were provided as follows: The age at vaccination was not reported. The patient accidentally received an adult dose of Havrix, which led to accidental overdose and adult product administered to child. The reporter consented to follow up.
Information has been received from a physician concerning a 17 year old female who on 30-AUG-2007 was vaccinated with Gardasil (Lot # not provided).  On 30-AUG-2007 post vaccination the patient experienced numbness in her arm that radiated and then numbness in her other arm.  The numbness then turned to pain.  It was reported that the patient also felt weak.  The patient's blood pressure was recorded at 80/60 mmHg which was reported to be slightly higher than before she felt weak.  Unspecified medical attention was sought.  At the time of the report it was reported that the patient was recovering.  Additional information has been requested.
Woke up with whole body aching, and had the chills. Went to work, started feeling dizzy, couldn't walk straight, fainted for a couple of minutes, couldn't move. Sent home. The next day, shoulder, neck, arm and hand are stiff, tight and numb.
Strong pain in deltoid muscle beginning the evening of the first injection (3/12) and the day after (3/13). Impossible to sleep on that arm, difficult to lift arm, severe pain when touched. Diminished pain 3/14-3/15.
Started with numbness and tingling down arm.  Developed red, hot, erythematous area about 2 cm distal to injection site.
Varicella vaccine administered age 1 year old.  This child exposed to Dx Case 12-25-02.  Lesions present 1-4-03.  Macule, vesicle, changing to pustule on 1-6-03.  Itching - no temperature noted.  Total lesions in various stages at time of report - ("12")
fever, swelling L arm, shoulder S.O.B given epinephrine 1:1000 0.3u SubQ & Kenelog 40mg IM with improvement
This case was reported by a consumer via call center representative and described the occurrence of adverse reaction in a male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown. It was unknown if the reporter considered the adverse reaction to be related to SHINGRIX. Additional details reported as follows: The age at vaccination was not reported. The patient had all of the side effects, and had question that how long would these last.
hot; temperature; cold; body aches; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (hot), BODY TEMPERATURE (temperature), NASOPHARYNGITIS (cold) and MYALGIA (body aches) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Apr-2021, the patient experienced FEELING HOT (hot), BODY TEMPERATURE (temperature), NASOPHARYNGITIS (cold) and MYALGIA (body aches). The patient was treated with PARACETAMOL (TYLENOL) for Pain, at an unspecified dose and frequency. At the time of the report, FEELING HOT (hot), BODY TEMPERATURE (temperature), NASOPHARYNGITIS (cold) and MYALGIA (body aches) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant drugs were reported.
Ophthalmic Trauma - Information has been received from a health care professional concerning a female physician who on 15 May 2000 was inadvertenly splashed in the eye with varicella virus vaccine live (lot 634491/0441k).  Unspecified medical attention was sought.  No further information is expected.
I have talked to numerous people who experienced temporary brain fog as a result of receiving the vaccine./ I can attest to that fact.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CONFUSIONAL STATE (non-serious), outcome "unknown", described as "I have talked to numerous people who experienced temporary brain fog as a result of receiving the vaccine./ I can attest to that fact.".  Additional information: Reporter repots that, I have talked to numerous people who experienced temporary brain fog as a result of receiving the vaccine. Especially the first shot. I can attest to that fact. I talked to a semi-truck driver who expressed the fact he was uncomfortable driving on a busy interstate. This point applies to commercial bus drivers and of course especially commercial aircraft pilots. I've had both shots and encourage everyone to do so. The issue of recipients operating machinery needs to be addressed.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Around 01/28/2023, I started with symptoms that I thought were a cold. I had a sore throat, coughing, fatigue, and a runny nose. I had a call from my daughter on 01/31/2023 informing me that she had tested positive for COVID-19. I went the next day, to an urgent care clinic. I tested positive for COVID-19, and they prescribed Paxlovid. I lost my sense of taste and smell. That lasted around three or four weeks, but it has returned now. I really didn't feel that bad throughout the whole thing.
This case was reported in a literature article and described the occurrence of glioblastoma multiforme in a 49-year-old male subject who was vaccinated with influenza vaccine unspecified (manufacturer unspecified). On an unspecified date the subject received unspecified dose of Influenza vaccine unspecified (unknown route, unknown lot number). At an unspecified time after vaccination with Influenza vaccine unspecified, the subject presented with a 2-week history of bilateral lower extremity weakness and paresthesia starting at the level of the axilla. The subject had a recent history of viral infection status post flu vaccination. He was evaluated by Neurology and initially diagnosed with transverse myelitis. He underwent intravenous immunoglobulin and steroid treatment without improvement. The subject's physical examination revealed 3/5 proximal and 5/5 distal muscle strength in the lower extremities, deep tendon reflexes were 2/4 with no upper motor neuron signs visualized. He was medically stabilized and transferred to our inpatient rehabilitation facility. Ten days post admission, the subject experienced acute motor loss (0/5) in bilateral lower extremities and worsening paresthesia, now involving bilateral upper extremities. At 10 days post admission, imaging revealed C7 to T2 diffuse cord expansion and an oval-shaped focus of intramedullary enhancement. Prior to the completion of his medical work-up the subject passed away due to unclear causes. The subject died from glioblastoma multiforme and respiratory failure. Post mortem autopsy results showed histopathological diagnosis of primary glioblastoma multiforme of the spinal cord.
5 days fever to 103 degrees. Maculopapular rash chest/ back/ face irritability
Liver function test decreased; Pain in arm; Rash over arms; This spontaneous case was reported by a consumer and describes the occurrence of LIVER FUNCTION TEST DECREASED (Liver function test decreased), PAIN IN EXTREMITY (Pain in arm) and RASH (Rash over arms) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis and Crohn's disease.    No medical history was provided by reporter.  No concomitant medication reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced LIVER FUNCTION TEST DECREASED (Liver function test decreased), PAIN IN EXTREMITY (Pain in arm) and RASH (Rash over arms). At the time of the report, LIVER FUNCTION TEST DECREASED (Liver function test decreased) had resolved and PAIN IN EXTREMITY (Pain in arm) and RASH (Rash over arms) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Liver function test: decreased but within normal range.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
receive the second dose >35 days after first dose; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receive the second dose >35 days after first dose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Stem cell transplant in February 2021. Concurrent medical conditions included Multiple myeloma and Immunocompromised (The transplant wiped out her immune system).   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receive the second dose >35 days after first dose). On 13-May-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receive the second dose >35 days after first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication information was reported. No Treatment medications were provided
Oral cavity sensitivity Narrative:  One day after 2nd dose; c/o heavy body rash appearing 02/19 - present that he is treating with a traditional medicine, red welts on chest and back, & frequent intermittent headache, & rawness & sensitivity in oral cavity.
This spontaneous report was received from a nurse refers to a patient of unknown age and gender. On 24-MAR-2014, the patient was administered a properly stored dose of ROTATEQ (dose and route not provided) (lot #H017672, expired on 19-MAR-2014). No adverse events were reported. Additional information has been requested.
Information has been received from a physician assistant via a company representative regarding a patient of unknown age and gender. On an unknown date, the patient was vaccinated with a dose of GARDASIL (dose and lot number were not provided). The company representative reported that a pharmacist, had requested information on 27-JAN-2014 about myasthenia gravis and GARDASIL with no patient involved. She stated that she learned today, 01-APR-2014 from another healthcare provider, a Physician Assistant, who had learned of the adverse experience from the pharmacist, that there was a patient involved in the inquiry posed on 27-JAN-2014. She stated that the patient was newly adopted patient and there was no medical history available. She stated that the patient received a dose of GARDASIL and was seen by an unspecified neurologist for symptoms of muscle weakness (date unspecified). The patient was diagnosed with myasthenia gravis (date unspecified) and the representative stated that the physician's assistant stated that an unspecified neurologist attributed the myasthenia gravis to the GARDASIL administration. The representative stated that the physician's assistant stated that the patient recovered and has no more symptoms, on unspecified date. Upon internal review the adverse event of myasthenia gravis was considered to be medically significant. Additional information is not expected.
Arms red, puffy and swollen. Fever on day 2 - none now. Rash on face -fading - not itching.
Administered MMR on 7/06/2016. Two days later developed a mild rash and low grade fever. Recovered 2-3 days later. Taken to clinic for treatment.
Pain in arm/sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Pain in arm/sore arm) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concomitant products included METHOTREXATE for an unknown indication.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) citrate free. On an unknown date, the patient experienced PAIN IN EXTREMITY (Pain in arm/sore arm). At the time of the report, PAIN IN EXTREMITY (Pain in arm/sore arm) had resolved.            On an unknown date, the patient experienced sore arm. On an unknown date, it was resolved. Moderna was also considered suspect. It was unknown if patient was enrolled in a COVID-19 vaccine trial.  No treatment medication was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Patient contacted me stating she was feeling light headed and her arm was tingly. Administered Moderna Covid-19 vaccine @ 8:30am, she was observed for 15 minutes, no adverse reaction at the time. At 1:45pm she stated she started feeling light headed around 12pm and it was not better. Her left arm (vaccine site) was painful and tinkly all the way down to her hand. I informed site administrator and patient was taken to the triage room when she stated she felt worst and was very pale.  FNP checked her pulse and respirations while Dr. was on the phone. Providers asked for her to be transferred to a room with a bed to lay down. Patient layed down her vituals were checked.  1:52pm BP-145/93 P- 66 T-97.7 R-18 2:03pm BP-117/77 P- 55 T-98.0 R-16 2:17pm BP-129/85 P- 59 T-97.8 R-16 Patient felt better after laying down for a few minutes and was send home to rest.
Had typical fever, chills, body ache & headache first 24 hours after vaccine. 48 hours later arm got red, hard and swollen below injection site. was painful to touch. a few hours that had splitting headache and neck pain and stiffness. had lab work done- all normal. took prophylactic antibiotics. arm was itchy now better.
Red swollen upper arm where vaccine was given.  Started about 16 hours afterwards.  That was a Thursday.  It is Sunday and arm still red and swollen and hurts.
Narrative:  Patient experienced body aches, chills, twitching, and fever after receiving the second dose of the COVID-19 vaccine.
The patient stated she has an itchy arm after her second dose, 10 min post injection.  She denied CP, SOB, itchy throat, cough.  She was given 50 mg  benadryl IM and 125 solumedrol IM. Observed 30 min without concern and sent home with precautions. Contacted 48 hours later and notes had fever, chills the night after injection. No itchiness or redness of injection sites.
This spontaneous report was received from a Bachelor of Science in Nursing reporting on herself who on an unknown date was vaccinated subcutaneously with a dose of ZOSTAVAX, 0.65 mL (lot # not provided). The patient received ZOSTAVAX and on an unspecified date experienced an injection site reaction. No specifics were given. No treatment was given for the event. The patient received medical attention and was not specific. On an unknown date, the patient recovered from the event. The relatedness for injection site reaction was unknown for ZOSTAVAX. Additional information has been requested.
pt recv vax 11OCT95 & 12OCT95 pt devel achiness & fever followed by diarrhea & mucousy foul-smelling stools;pt further c/o nausea;pt recovered from above sx